Test confirms antiplatelet effectiveness of aspirin in new super pill
ORLANDO, Fla. and DENVER, March 31 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX) announced today that its AspirinWorks Test was used by investigators in The Indian POLYCAP Study (TIPS) to help determine patients' response to aspirin and/or statin therapy.
The TIPS trial examined the effect of combinations of aspirin, statin and three blood-pressure-lowering drugs on blood pressure, lipids, heart rate and urinary 11-dehydrohtromboxane B2 (11dTxB2) as measured by the AspirinWorks Test in more than 2,000 individuals.
Results of the randomized, controlled, double-blind study were presented as a late breaking clinical trial March 30 at the American College of Cardiology (ACC) 58th Annual Scientific Sessions in Orlando, Fla. Corgenix is exhibiting its test in Booth No. 1162 during ACC.09.
Overall results showed that the single combination pill was about as effective as taking the five drugs individually and was well tolerated. Trial results also showed that randomization to aspirin therapy resulted in a reduction in 11dTxB2, validating the findings of the previous CHARISMA trial.
"The use of the AspirinWorks Test in this large, groundbreaking trial demonstrates the value of understanding a patient's individual response to aspirin, and the ability of our test to accurately and consistently determine that response," said Gordon Ens, Corgenix Director of Clinical Affairs.
The TIPS trial is the largest to date to test the theory that a single, low-cost, easy-to-take "super pill" can be used to reduce cardiovascular risk across a large population as effectively as several individual pills.
The AspirinWorks Test measures urinary 11dhTxB2, identified in the previously published CHARISMA trial as an independent predictor of risk modifiable by aspirin and statin therapy. The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.
The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest Diagnostics, LabCorp and SpectraCell.
Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office or patient service center, making the test convenient for both physician and patient.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
|SOURCE Corgenix Medical Corporation|
Copyright©2009 PR Newswire.
All rights reserved